Deals Of The Week: Roche/Galaxy, Mallinckrodt/CNS Therapies, Valeant/QLT
Executive Summary
Cardiome may go it alone with atrial fibrillation drug vernakalant after Merck exited a 2009 partnership around the drug, but another possibility is that Cardiome will seek a buyer.
You may also be interested in...
QLT Shows Off Its Assets In Hopes Of Attracting A Suitor
The Canadian biotech has put itself on the block after a year of changes that have transformed the company from a commercial-stage entity with pipeline assets to a one-drug tax play.
Covidien’s Mallinckrodt To Buy CNS Therapeutics For $100M
Covidien’s pharmaceutical arm Mallinckrodt has announced its plans to acquire St. Paul, MN-based CNS Therapeutics for $100 million. The acquisition will complement Mallinckrodt’s own generic pain therapeutic offerings. Mallinckrodt is on track to be spun out of Covidien in mid-2013.
Merck Drops Development Of Cardiome’s Oral Vernakalant
Higher regulatory hurdles for anti-arrhythmic drugs have pushed Merck to discontinue the development of Cardiome’s oral vernakalant.